SCHEMBL10191692

SCHEMBL10191692

CN(C)/C=C1/CCCc2nn(C)cc2C1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.43
▸ GAA P10253 3/20 0.43
▸ MAPT P10636 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ HTR1A P08908 3/20 0.33
▸ DRD2 P14416 3/20 0.33
▸ HTR2A P28223 3/20 0.33
▸ CYP1A2 P05177 1/20 0.31
▸ ACHE P22303 1/20 0.31
▸ ELANE P08246 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ NFKB1 P19838 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ NFKB2 Q00653 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10191696 0.91 KDM4E (0.39) ALDH1A1GAAMAPTHTTMEN1
SCHEMBL10191693 0.82 ALDH1A1 (0.46) ALDH1A1GAAMAPTHTTMEN1
SCHEMBL10191680 0.82 KDM4E (0.35) ALDH1A1GAAMAPTHTTMEN1
SCHEMBL10191694 0.74 IKBKB (0.39) MEN1KMT2AKDM4E
SCHEMBL10191699 0.73 KDM4E (0.36) ALDH1A1MEN1KMT2AKDM4EHTR1A
SCHEMBL10191704 0.73 IKBKB (0.43) MEN1KMT2AKDM4E
SCHEMBL10192400 0.73 ELANE (0.51) ALDH1A1GAAMAPTHTTKDM4E
SCHEMBL10191730 0.71 ALDH1A1 (0.38) ALDH1A1GAAMAPTHTTSMN1; SMN2
SCHEMBL10191421 0.70 — —
SCHEMBL9210990 0.70 ELANE (0.47) ALDH1A1GAAMAPTHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2595987-B1 NEW AMINOPYRAZOLOQUINAZOLINES BOEHRINGER INGELHEIM INT (DE) 2018-04-18 — — EP disclosed
US-8735386-B2 Aminopyrazoloquinazolines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-05-27 — — US disclosed
US-8735386-B2 Aminopyrazoloquinazolines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-05-27 — — US disclosed
US-20120238542-A1 AMINOPYRAZOLOQUINAZOLINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-09-20 — — US disclosed
US-20120238542-A1 AMINOPYRAZOLOQUINAZOLINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-09-20 — — US disclosed
WO-2012010704-A1 NEW AMINOPYRAZOLOQUINAZOLINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238542-A1 AMINOPYRAZOLOQUINAZOLINES CCNT1, CCNI, MKI67 ALDH1A1 401/4885GAA 1440/4885MAPT 3841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback